Atlas Trials

A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)

Clinical trial NCT00571675 · COMPLETED

Trial details

NCT number
NCT00571675
Sponsor
Ascenta Therapeutics
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Hormone Refractory Prostate Cancer
Start date
2007-10-01
Primary completion
2010-09-01
Enrollment
220

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.